^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pimivalimab (JTX-4014)

    i
    Other names: JTX 4014, JTX4014, JTX-4014
    Company:
    Concentra Biosci
    Drug class:
    PD1 inhibitor
    Related drugs:
    2ms
    Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, Jounce Therapeutics, Inc. | Trial primary completion date: Sep 2022 --> May 2024
    Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    pimivalimab (JTX-4014) • vopratelimab (JTX-2011)
    3ms
    INNATE: Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=190, Completed, Jounce Therapeutics, Inc. | Active, not recruiting --> Completed | N=281 --> 190
    Trial completion • Enrollment change • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR (Fibroblast Growth Factor Receptor)
    |
    EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation
    |
    pimivalimab (JTX-4014) • polzastobart (JTX-8064)
    10ms
    Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, Jounce Therapeutics, Inc. | Trial completion date: Mar 2023 --> May 2024
    Trial completion date • Combination therapy • IO biomarker • Metastases
    |
    pimivalimab (JTX-4014) • vopratelimab (JTX-2011)
    1year
    INNATE: Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=281, Active, not recruiting, Jounce Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR (Fibroblast Growth Factor Receptor)
    |
    EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation
    |
    pimivalimab (JTX-4014) • polzastobart (JTX-8064)
    over2years
    INNATE: Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=281, Recruiting, Jounce Therapeutics, Inc. | Phase classification: P1 --> P1/2
    Phase classification • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement
    |
    pimivalimab (JTX-4014) • polzastobart (JTX-8064)
    over2years
    INNATE: Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=281, Recruiting, Jounce Therapeutics, Inc. | N=40 --> 281 | Trial completion date: Sep 2022 --> Jan 2024 | Trial primary completion date: Jul 2022 --> Sep 2023
    Clinical • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement
    |
    pimivalimab (JTX-4014) • polzastobart (JTX-8064)
    3years
    [VIRTUAL] Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT). (ASCO 2021)
    The preliminary efficacy of vopratelimab +/- nivolumab was assessed in the phase 1/2 ICONIC study in which durable responses were observed in a subset of patients who demonstrated on treatment emergence of peripheral ICOS hi CD4 T effector cells . Secondary endpoints include ORR and PFS according to RECIST v1.1, OS, safety, and association of baseline TIS score with clinical outcomes . The study has a target enrollment goal of approximately 75 patients; the first patient was dosed October 2020.
    Clinical • P2 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • CD4 (CD4 Molecule) • ICOS (Inducible T Cell Costimulator)
    |
    EGFR mutation
    |
    Opdivo (nivolumab) • pimivalimab (JTX-4014) • vopratelimab (JTX-2011)